No­vo Nordisk nabs pri­or­i­ty re­view vouch­er for $110M from Mar­i­nus as the biotech preps first drug launch

When Mar­i­nus Phar­ma­ceu­ti­cals com­plet­ed its turn­around and fi­nal­ly pushed its sole drug across the FDA fin­ish line, the com­pa­ny not­ed it would sell the pri­or­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER